EUVIMEDEUVIMED entdecken
Crossref

Development and Preclinical Evaluation of a Novel 68Ga/177Lu-Labeled Nanobody for Radiotheranostics of HER2-Positive Tumors

Lingzhou Zhao iD, Liyan Bai, Li Sun, Xinyu Liu, Xin Lu, Jianping Zhang, Xiaoping Xu, Shaoli Song iD

Journal of Medicinal Chemistry · 23.04.2026 · 69 (8) · 9757-9770

DOI: 10.1021/acs.jmedchem.6c00837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.04.2026. Verfasst von Lingzhou Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Gallium Radioisotopes, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) is overexpressed in various malignancies, making it an attractive target for radiotheranostics. Nanobodies offer an ideal platform for radiopharmaceutical development. Here, we reported a novel HER2-specific nanobody (NB46) engineered with a C-terminal glycine-serine-cysteine (GSC) tripeptide for site-specific NOTA conjugation and radiolabeling with 68Ga and 177Lu. [68Ga]Ga/[177Lu]Lu-NOTA-NB46 exhibited high HER2 affinity and specificity in vitro. In HER2-positive tumor-bearing mice, the radiotheranostic agents showed rapid blood clearance, favorable biodistribution, high tumor accumulation, and low nontarget uptake. [177Lu]Lu-NOTA-NB46 demonstrated prolonged tumor retention. Single-dose therapy with [177Lu]Lu-NOTA-NB46 significantly inhibited tumor growth and extended survival in a dose-dependent manner with good tolerability. The kidneys were the primary dose-limiting organ. [68Ga]Ga/[177Lu]Lu-NOTA-NB46 represents a promising radiotheranostic pair for HER2-positive tumors, supporting its further translation into clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsGallium RadioisotopesErb-b2 Receptor Tyrosine KinasesLutetiumCell Line, TumorTheranostic NanomedicineHumansAnimalsMiceMice, Nude

Substanzen

RadiopharmaceuticalsLutetiumGallium RadioisotopesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China.

ORCID-Profile: Lingzhou Zhao, Shaoli Song

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Nuclear Technology Research and Development Program
  • Shanghai Oriental Talents Program Youth Project
  • Shanghai Collaborative Innovation Project

Zitieren

APA

Zhao, L., Bai, L., Sun, L., Liu, X., Lu, X., Zhang, J., Xu, X., & Song, S. (2026). Development and Preclinical Evaluation of a Novel 68Ga/177Lu-Labeled Nanobody for Radiotheranostics of HER2-Positive Tumors. Journal of Medicinal Chemistry, 69(8), 9757-9770. https://doi.org/10.1021/acs.jmedchem.6c00837

Vancouver

Zhao L, Bai L, Sun L, Liu X, Lu X, Zhang J, et al. Development and Preclinical Evaluation of a Novel 68Ga/177Lu-Labeled Nanobody for Radiotheranostics of HER2-Positive Tumors. Journal of Medicinal Chemistry. 2026;69(8):9757-9770. doi:10.1021/acs.jmedchem.6c00837

BibTeX
@article{Zhao2026,
  author = {Zhao, Lingzhou and Bai, Liyan and Sun, Li and Liu, Xinyu and Lu, Xin and Zhang, Jianping and Xu, Xiaoping and Song, Shaoli},
  title = {Development and Preclinical Evaluation of a Novel 68Ga/177Lu-Labeled Nanobody for Radiotheranostics of HER2-Positive Tumors},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {8},
  pages = {9757--9770},
  doi = {10.1021/acs.jmedchem.6c00837}
}
Kostenlos starten →